Immunotherapy for advanced melanoma: Future directions

Sara Valpione, Luca G. Campana

Research output: Contribution to journalArticlepeer-review


As calculated by the meta-analysis of Korn et al., the prognosis of metastatic melanoma in the pretarget and immunological therapy era was poor, with a median survival of 6.2 and a 1-year life expectancy of 25.5%. Nowadays, significant advances in melanoma treatment have been gained, and immunotherapy is one of the promising approaches to get to durable responses and survival improvement. The aim of the present review is to highlight the recent innovations in melanoma immunotherapy and to propose a critical perspective of the future directions of this enthralling oncology subspecialty.

Original languageEnglish
Pages (from-to)199-209
Number of pages11
Issue number2
Publication statusPublished - Feb 1 2016
Externally publishedYes


  • anti-inhibitory checkpoints
  • cellular therapy
  • immunotherapy
  • melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology


Dive into the research topics of 'Immunotherapy for advanced melanoma: Future directions'. Together they form a unique fingerprint.

Cite this